Viridian Therapeutics
Open
$13.38
Prev. Close
$13.38
High
$13.38
Low
$13.38
Market Snapshot
$1.27B
-3.7
-3.05
$302K
252
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 252 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. The company is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
emptyResult
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 252 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. The company is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Recently from Cashu
Viridian Therapeutics Advances Proptosis Treatment with Promising Elegrobart Trial Results
Promising Advancements in Proptosis Treatment with Elegrobart Viridian Therapeutics is making significant strides in the treatment of proptosis, demonstrated by its recent REVEAL-1 trial involving the…
REVEAL-1 Trial Shows Promising Efficacy of Elegrobart for Proptosis Treatment
Promising Advances in Proptosis Treatment: Elegrobart's Efficacy Revealed in REVEAL-1 Trial The recent results from the REVEAL-1 trial mark a significant advancement in the treatment landscape for pro…
Viridian Therapeutics Reports Strong Q4 Growth and Commitment to Innovative Therapeutics
Viridian Therapeutics: Sustained Growth in Innovative Therapeutics Viridian Therapeutics showcases notable progress in its Q4 earnings report released on February 26, 2026. The report reveals that the…
Viridian Therapeutics Reports Strong Q4 Earnings, Highlighting Innovation and Strategic Growth Plans
Viridian Therapeutics: Driving Innovation in Therapeutics through Strategic Growth and Research Investments Viridian Therapeutics, a notable player in the biotechnology sector, delivers strong perform…